Page last updated: 2024-08-05 12:38:06
12alpha-hydroxy steroid
null
ChEBI ID: 36846
Members (11)
Member | Definition | Role |
---|---|---|
3,7,12-trihydroxycholestan-26-oic acid | A steroid acid that is 5beta-cholestan-26-oic acid which is substituted by hydroxy groups as the 3alpha, 7alpha, and 12alpha positions. | 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oic acid |
3,7,12-trihydroxycoprostane | 5beta-cholestane-3alpha,7alpha,12alpha-triol | |
3,7,12-trihydroxycoprostanic acid | 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestane-5-carboxylic acid | |
3,7,12,24-tetrahydroxycholestanoic acid | 3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid | |
3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by hydroxy groups at positions 3 and 12, a methyl group at position 4 and oxo groups at positions 7 and 11 (the 3alpha,4alpha,5alpha,12alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits antineoplastic activity. | zhankuic acid C |
allocholic acid | An allo-bile acid that is 5alpha-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12. | allocholic acid |
cholestane-3,7,12,26-tetrol | 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol | |
cholic acid | A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12. | cholic acid |
scymnol | 5beta-scymnol | |
tenuigenin | Senegenin | |
ursocholic acid | A bile acid that is 5beta-cholan-24-oic acid bearing three hydroxy substituents at positions 3alpha, 7beta and 12alpha. | ursocholic acid |
Research
Studies (2,025)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 508 (25.09) | 18.7374 |
1990's | 466 (23.01) | 18.2507 |
2000's | 409 (20.20) | 29.6817 |
2010's | 495 (24.44) | 24.3611 |
2020's | 147 (7.26) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 43 (2.01%) | 5.53% |
Reviews | 33 (1.54%) | 6.00% |
Case Studies | 32 (1.49%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 2,033 (94.96%) | 84.16% |